The Evolution of Latent Tuberculosis Infection Regimens And Analysis of The Completion Rates, Taiwan, 2016–2022

DOI: 10.6524/EB.202403_40(6).0002

Shu-Chun Liao, Pei-Fang Lai, Hsiu-Yun Lo^*, Chi-Fang Feng, Pin-Hui Lee, Pei-Chun Chan, Chia-Chi Lee

2024 Vol.40 NO.6

Correspondence Author： Hsiu-Yun Lo^*

Abstract：

        Treating latent tuberculosis infection (LTBI) is an important strategy for achieving TB elimination. Due to its effectiveness and safety, Isoniazid (INH) is the preferred regimen worldwide. However, the longer treatment duration of 6-12 months has resulted in lower completion rates. In line with the World Health Organization guidelines and international experience, Taiwan’s National TB Program has updated its LTBI treatment guidelines to include shorter regimens such as 3HP, 4R, 3HR, and 1HP as alternative options. This retrospective study aimed to analyze the LTBI treatment regimens and compare the completion rates between 2016 and 2022, using the TB database obtained from the Taiwan Centers for Disease Control, to illustrate the progress and scaling up of LTBI treatment in Taiwan.